Sabbatini 2012.

Methods	Uncontrolled phase I study
Participants	28 ovarian cancer patients in second or third remission
Interventions	Subcutaneous overlapping long peptides (NY‐ESO‐1) Adjuvant: cohort 1 ‐ no (n = 4); cohort 2: Montanide ISA‐51 (n = 13); cohort 3: poly‐ICLC in Montanide ISA‐51 (n = 11)
Outcomes	Survival (time to progression) Tumour responses Immune responses: cellular and humoral Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Uncontrolled trial
Allocation concealment (selection bias)	High risk	Uncontrolled trial
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’